Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Artemether

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Artemether
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Artemisinin and derivatives, plain
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BE02; WHO ATC P01BE05

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Artemether, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis22.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Artemether in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Artemether with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...

    NCT03952650 · start 2019-05-23

    Registered record
    Registry ID
    NCT03952650
    Conditions
    Malaria
    Interventions
    Chloroquine Phosphate; PfSPZ Challenge; Pyrimethamine; Coartem; ibuprofen
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-05-23
    Completion
    2021-02-10
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionChloroquine Phosphate; PfSPZ Challenge; Pyrimethamine; Coartem +1 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine

    NCT05192265 · start 2019-05-20

    Registered record
    Registry ID
    NCT05192265
    Conditions
    Malaria Fever; Plasmodium Falciparum Malaria; Uncomplicated Malaria
    Interventions
    Antimalarials, pyronaridine-artesunate; Antimalarials, Artemether + Lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2019-05-20
    Completion
    2020-12-23
    Enrolment
    172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria Fever; Plasmodium Falciparum Malaria; Uncomplicated Malaria
    InterventionAntimalarials, pyronaridine-artesunate; Antimalarials, Artemether + Lumefantrine
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Feasibility, Acceptability and Costs of a Multiple First-lines Artemisinin-based Combination Therapies

    NCT04265573 · start 2018-11-10

    Registered record
    Registry ID
    NCT04265573
    Conditions
    Malaria
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-11-10
    Completion
    2021-02-25
    Enrolment
    150,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Dried Leaf Artemisia (DLA) Compared to Artemisinin Combination Therapy (ACT) vs Malaria

    NCT03199755 · start 2018-08-20

    Registered record
    Registry ID
    NCT03199755
    Conditions
    Malaria
    Interventions
    ACT; DLA1; DLA2
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2018-08-20
    Completion
    2019-10-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionACT; DLA1; DLA2
    PhasePhase 2
    Registry statusWithdrawn

  • Extended Duration Artemether-lumefantrine Treatment for Malaria in Children

    NCT03453840 · start 2018-02-21

    Registered record
    Registry ID
    NCT03453840
    Conditions
    Uncomplicated Plasmodium Falciparum Malaria
    Interventions
    Artemether-lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-02-21
    Completion
    2021-08-31
    Enrolment
    305

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Plasmodium Falciparum Malaria
    InterventionArtemether-lumefantrine
    PhasePhase 4
    Registry statusCompleted

  • Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer (NeoART-V)

    NCT03093129 · start 2018-01-08

    Registered record
    Registry ID
    NCT03093129
    Conditions
    Colorectal Cancer
    Interventions
    artesunate; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-01-08
    Completion
    2022-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventionartesunate; placebo
    PhasePhase 2
    Registry statusUnknown

  • "Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in Bagamoyo District, Tanzania"

    NCT03241901 · start 2017-07-27

    Registered record
    Registry ID
    NCT03241901
    Conditions
    Malaria,Falciparum
    Interventions
    Artemether-Lumefantrine Tab 20-120mg; Primaquine Phosphate 0.25 mg/kg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-07-27
    Completion
    2018-02-17
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria,Falciparum
    InterventionArtemether-Lumefantrine Tab 20-120mg; Primaquine Phosphate 0.25 mg/kg; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers

    NCT03163121 · start 2017-05-12

    Registered record
    Registry ID
    NCT03163121
    Conditions
    Malaria
    Interventions
    PfSPZ-GA1 Vaccine; PfSPZ Vaccine; Normal Saline; Mosquito-bite CHMI
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-05-12
    Completion
    2018-10-25
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionPfSPZ-GA1 Vaccine; PfSPZ Vaccine; Normal Saline; Mosquito-bite CHMI
    PhasePhase 1
    Registry statusCompleted

  • Integrated Community Case Management Study in Eastern Province, Zambia

    NCT02866097 · start 2016-03

    Registered record
    Registry ID
    NCT02866097
    Conditions
    Malaria; Diarrhea; Pneumonia
    Interventions
    mHealth inventory management; Supportive supervision; ICCM current standard of care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-03
    Completion
    2016-09
    Enrolment
    3,840

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Diarrhea; Pneumonia
    InterventionmHealth inventory management; Supportive supervision; ICCM current standard of care
    PhaseNot applicable
    Registry statusUnknown

  • Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration

    NCT02654912 · start 2016-02

    Registered record
    Registry ID
    NCT02654912
    Conditions
    Malaria
    Interventions
    Reactive Focal Drug Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-02
    Completion
    2020-07
    Enrolment
    8,682

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionReactive Focal Drug Administration
    PhasePhase 4
    Registry statusCompleted

  • Artemether-lumefantrine Resistance Monitoring in Children With Uncomplicated Plasmodium Falciparum Malaria in Mali

    NCT02645604 · start 2016-01-01

    Registered record
    Registry ID
    NCT02645604
    Conditions
    Accute Falciparum Malaria
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-01-01
    Completion
    2018-12-14
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAccute Falciparum Malaria
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)

    NCT02453308 · start 2015-08

    Registered record
    Registry ID
    NCT02453308
    Conditions
    Malaria, Falciparum
    Interventions
    ACT; TACT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2015-08
    Completion
    2018-03
    Enrolment
    1,110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Falciparum
    InterventionACT; TACT
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Malawi International Center of Excellence in Malaria Research School-based Cohort

    NCT04858087 · start 2015-03-24

    Registered record
    Registry ID
    NCT04858087
    Conditions
    Malaria; Malaria,Falciparum; Anemia
    Interventions
    Screening and treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-03-24
    Completion
    2015-11-13
    Enrolment
    786

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Malaria,Falciparum; Anemia
    InterventionScreening and treatment
    PhaseNot recorded
    Registry statusCompleted

  • Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia

    NCT02325180 · start 2015-01

    Registered record
    Registry ID
    NCT02325180
    Conditions
    Malaria, Falciparum
    Interventions
    Dihydroartemisinin-Piperaquine; Artemether-lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-01
    Completion
    2015-06
    Enrolment
    338

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Falciparum
    InterventionDihydroartemisinin-Piperaquine; Artemether-lumefantrine
    PhasePhase 4
    Registry statusCompleted

  • Relapses in Plasmodium Ovale and Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria

    NCT02528279 · start 2014-10

    Registered record
    Registry ID
    NCT02528279
    Conditions
    Malaria
    Interventions
    Coartem
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-10
    Completion
    2016-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionCoartem
    PhaseNot applicable
    Registry statusCompleted